This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
bulimia-nervosa
Bulimia Nervosa
Eating disorder characterized by binge eating + compensatory behaviors (purging, fasting, exercise) ≥1/week × 3 months at normal weight. Serotonin hypofunction drives impulsivity; fluoxetine 60 mg is FDA-approved. CBT-BN is first-line treatment.
Entry Metadata
| Field | Value |
|---|---|
| ID | bulimia-nervosa |
| Name | Bulimia Nervosa |
| Status | draft |
| Last reviewed | 2026-06-08 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Fairburn CG. Cognitive Behavior Therapy and Eating Disorders. Guilford Press; 2008.
- Kaye WH, Fudge JL, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nat Rev Neurosci. 2009;10(8):573-584. · PubMed 19603056
- Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry. 1992;49(2):139-47. · PubMed 1550466